Overview

Nicotinamide Riboside as an Enhancer of Exercise Therapy in Hypertensive Older Adults (The NEET Trial)

Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
More than 80% of older adults have hypertension, with higher prevalence of high systolic blood pressure (SBP) putting them at high risk for cardiovascular (CV) disease and death. Novel compound, nicotinamide riboside may enhance the effects of exercise therapy in hypertensive older adults.
Phase:
Phase 1
Details
Lead Sponsor:
University of Florida
Collaborator:
National Institute on Aging (NIA)
Treatments:
Niacin
Niacinamide
Nicotinic Acids